Cite
HARVARD Citation
Dudnik, E. et al. (2021). Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data. Oncoimmunology. p. . [Online].